Last update 01 Apr 2025

Empasiprubart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
empasiprubart, ARGX 117, ARGX-117
Target
Action
inhibitors
Mechanism
C2 inhibitors(complement C2 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multifocal Motor NeuropathyPhase 3
United States
18 Dec 2024
DermatomyositisPhase 2
United States
20 Aug 2024
DermatomyositisPhase 2
Georgia
20 Aug 2024
DermatomyositisPhase 2
Greece
20 Aug 2024
DermatomyositisPhase 2
Italy
20 Aug 2024
DermatomyositisPhase 2
Poland
20 Aug 2024
DermatomyositisPhase 2
Spain
20 Aug 2024
Delayed Graft FunctionPhase 2
United States
17 Feb 2024
Delayed Graft FunctionPhase 2
Australia
17 Feb 2024
Delayed Graft FunctionPhase 2
Austria
17 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
xmnnddjplf(iugtoiezlj) = most were mild or moderate hpfbspxwid (blvypmyypp )
Positive
25 Jun 2024
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free